Dipal Doshi
President and CEO at Entrada Therapeutics Inc.
Sits on 2 boards. Last updated September 27, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 5 years
- Director since
- 2023
5 years of board service in total across 2 boards, counting each seat separately. Longest: Entrada Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Azenta Inc. January 28, 202682.6%
-
Azenta Inc. January 30, 202598.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 2, 2026 | Entrada Therapeutics Inc. | Shares withheld for tax | −8,724 | $7.14 | $62,323 |
| Mar 3, 2026 | Entrada Therapeutics Inc. | Shares withheld for tax | −19,181 | $11.76 | $225,569 |
| Mar 2, 2026 | Entrada Therapeutics Inc. | Shares withheld for tax | −9,869 | $11.66 | $115,073 |
| Mar 1, 2026 | Entrada Therapeutics Inc. | Grant or award | +139,400 | — | — |
| Feb 5, 2026 | Azenta Inc. | Grant or award | +5,663 | $27.85 | $157,715 |
| Sep 2, 2025 | Entrada Therapeutics Inc. | Shares withheld for tax | −8,723 | $5.43 | $47,366 |
| Mar 3, 2025 | Entrada Therapeutics Inc. | Shares withheld for tax | −17,566 | $11.68 | $205,171 |
| Mar 1, 2025 | Entrada Therapeutics Inc. | Grant or award | +116,200 | — | — |
| Feb 7, 2025 | Azenta Inc. | Grant or award | +4,040 | $52.32 | $211,373 |
| Sep 5, 2024 | Entrada Therapeutics Inc. | Shares withheld for tax | −826 | $15.13 | $12,497 |
| Sep 4, 2024 | Entrada Therapeutics Inc. | Shares withheld for tax | −4,744 | $15.42 | $73,152 |
| Sep 3, 2024 | Entrada Therapeutics Inc. | Shares withheld for tax | −2,328 | $15.76 | $36,689 |
| Sep 3, 2024 | Entrada Therapeutics Inc. | Shares withheld for tax | −752 | $16.93 | $12,731 |
| Sep 3, 2024 | Entrada Therapeutics Inc. | Shares withheld for tax | −72 | $17.70 | $1,274 |
| Jul 15, 2024 | Entrada Therapeutics Inc. | Open-market sale | −1,600 | $17.81 | $28,496 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.